Tenofovir disoproxil (as fumarate) (Viread®) film-coated tablets are recommended as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adolescent and paediatric patients, with nucleoside reverse transcriptase inhibitor (NRTI) resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years (245 mg tablets) and aged 6 to < 12 years who weigh from 17 kg to less than 22 kg (123 mg tablets), 22 kg to less than 28 kg (163 mg tablets) and 28 kg to less than 35 kg (204 mg tablets). Tenofovir disoproxil (as fumarate) (Viread®) 33 mg/g granules are recommended as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected paediatric patients, with NRTI resistance or toxicities precluding the use of first line agents, from 2 to < 6 years of age, and above 6 years of age for whom a solid dosage form is not appropriate. The choice of tenofovir disoproxil to treat antiretroviral-experienced patients with HIV-1 infection should be based on individual viral resistance testing and/or treatment history of patients.